Indian Journal of Drugs in Dermatology

ORIGINAL ARTICLE
Year
: 2022  |  Volume : 8  |  Issue : 2  |  Page : 59--65

Bilastine in pruritus associated with dermatological conditions


Abhay Talathi1, Prajakta Talathi1, Jalpa Kapadia Rachh2, Kaleem Khan3, Dhiraj Dhoot4, Gaurav Anil Deshmukh4 
1 Consultant Dermatologist, Skinspace Clinic, Mumbai, Maharashtra, India
2 Consultant Dermatologist, Devasya Skin Care Clinic, Mumbai, Maharashtra, India
3 Consultant Dermatologist, Skin indulgence Clinic, Mumbai, Maharashtra, India
4 Global Medical Affairs, Glenmark Pharmaceuticals Ltd, Mumbai, Maharashtra, India

Correspondence Address:
Abhay Talathi
Consultant Dermatologist, Skinspace Clinic, Mumbai, Maharashtra
India

Introduction: Pruritus is a common and unpleasant symptom associated with multiple skin diseases. As histamine plays a central role in pruritus pathology, H1 antihistamines are frequently used in its management. Bilastine is a potent second-generation antihistamine approved for the management of urticaria. However, there are few studies showing its effectiveness and safety in pruritus associated with skin diseases. Materials and Methods: In this multicenter, open-label study, patients with pruritus associated with various skin diseases received bilastine 20 mg once daily for 4 weeks. Patients were evaluated for improvement in their pruritus based on the 5D itch score and Dermatology Life Quality Index (DLQI). Safety of bilastine was assessed by monitoring the incidence of adverse events during the study period. Results: A total of 116 patients with urticaria (n = 22), eczema/dermatitis (n = 27), lichen planus (n = 9), pPsoriasis (n = 11), dermatophytosis (n = 42), and others (n = 5) were included in the study. There was a significant improvement in the 5D itch score at the end of therapy (16.18 ± 2.81 vs. 6.20 ± 1.38 P < 0.0001) in all patients. Bilastine improved the DLQI at week 4 in all disease groups (11.83 ± 4.97 vs. 2.15 ± 2.68; P < 0.0001). The treatment was well tolerated. Conclusion: Bilastine is associated with significant improvement in pruritus associated with multiple dermatological disorders with a very good safety profile.


How to cite this article:
Talathi A, Talathi P, Kapadia Rachh J, Khan K, Dhoot D, Deshmukh GA. Bilastine in pruritus associated with dermatological conditions.Indian J Drugs Dermatol 2022;8:59-65


How to cite this URL:
Talathi A, Talathi P, Kapadia Rachh J, Khan K, Dhoot D, Deshmukh GA. Bilastine in pruritus associated with dermatological conditions. Indian J Drugs Dermatol [serial online] 2022 [cited 2023 Feb 8 ];8:59-65
Available from: https://www.ijdd.in/article.asp?issn=2455-3972;year=2022;volume=8;issue=2;spage=59;epage=65;aulast=Talathi;type=0